38 results about "Visceral fat" patented technology

Methods and compositions using Dichrostachys glomerata or Cissus quadrangularis separately to provide a variety of health benefits, including but not limited to, increase GLP-1 levels and reduce or decrease visceral fat, food intake, blood lipids, total cholesterol and total glucose in a mammal. In one embodiment, a composition for reducing visceral fat in a mammal is provided where the composition comprises an effective amount of Cissus quadrangularis provided as an oral dosage unit in the form of a pill, capsule, liquid, lozenge or tablet.

The invention discloses a limb multi-frequency rapid visceral fat measuring method and device, and the method comprises the steps: configuring a sensor which comprises four pairs of electrodes connected with limbs and a waistline sensor surrounding the waist; the visceral fat amount is calculated according to the measurement results of the electrodes of the limbs and the waistline sensor. Eight electrodes are matched with the waistline sensor for measurement, and the non-visceral fat amount of the human body can be calculated more accurately and quickly through multi-dimensional and multi-frequency complex impedance measurement.

The invention relates to application of DOP (dioctyl phthalate) in preparation of medicines for regulating lipid metabolism, resisting diabetes and resisting intestinal microorganisms. The DOP significantly alleviates DIO by inhibiting the expansion of lipid droplets (LD) in white adipose tissue (WAT) and down-regulating LD-related genes (including PLIN2 and PLIN3). DOP can target visceral fat, significantly improve visceral fat hypertrophy and hyperplasia (especially epididymal fat EAT is taken as aboriginal) induced by high fat diet (HFD), inhibit formation of lipid droplets, reduce expression of lipid droplet coating protein PLIN2 / 3, and block the accumulation process of lipid droplets (LD). Consistent with we have observed that DOP also inhibits the expression of genes associated with lipid synthesis and adipogenesis, including Fabp1, Fast, Ldlr, Cebpb, and Dio2. These findings show that DOP can improve diet-induced obesity by regulating lipid droplet-related pathways.

Methods and compositions using Dichrostachys glomerata or Cissus quadrangularis separately to provide a variety of health benefits, including but not limited to, increase GLP-1 levels and reduce or decrease visceral fat, food intake, blood lipids, total cholesterol and total glucose in a mammal. In one embodiment, a composition for reducing fasting blood glucose in a mammal is provided where the composition comprises an effective amount of Dichrostachys glomerata provided as an oral dosage unit in the form of a pill, capsule, liquid, lozenge or tablet.

Methods and uses are presented in which a therapeutically effective unit dose of dodecanedioic acid (DDDA or DC12) is administered for an extended period of time to improve a subject's lipid metabolism. Preferred dosage units comprise no more than 5% of the subject's standard daily caloric intake and improvements in metabolism are associated with weight loss and / or reduction of visceral fat.

The present invention relates to a microbiome composition of the fermentation culture supernatant of the halophilic Bacillus polyfermenticus KMU01 strain, which has anti-obesity effects. It has been confirmed that the fermentation culture supernatant of the strain deposited under accession number KCTC11751BP inhibits fat production and accumulation and reduces blood cholesterol levels. Therefore, the composition can be usefully used as a composition for preventing, treating, or ameliorating obesity; or as a composition for reducing body fat (visceral fat) or blood cholesterol.

The use of a postbiotic of Bifidobacterium brevis 207-1 (GDMCC No. 60962) or a composition containing the postbiotic in the preparation of a medicine or a food product. The medicine or food product is used for preventing and / or ameliorating diseases and / or symptoms related to fat gain in a subject. The diseases and / or symptoms are selected from weight gain, obesity, fatty liver, fat accumulation (e.g., visceral fat accumulation and subcutaneous fat accumulation), abnormal lipid metabolism, or any combination thereof. The medicine or food product can promote the fat breakdown and / or inhibit the fat absorption, maintain or reduce the body weight and / or BMI of the subject, increase the satiety of the subject, and reduce the food intake of the subject.

The use of an RINL gene and an antagonist thereof in the treatment of obesity. Specifically provided is the use of an RINL gene or an encoded protein thereof. The RINL gene or the encoded protein thereof is used for one of the following: (1) as a marker for diagnosing, detecting or prognosing obesity; (2) in the preparation of a reagent or kit for diagnosing or detecting obesity; or (3) in the preparation of a drug for treating obesity. RINL-KO significantly improves glucose tolerance and insulin resistance of obese mice, ameliorates the accumulation of subcutaneous fat and visceral fat thereof, alleviates the inflammation of adipose tissue thereof, and greatly improves the health of the mice. Therefore, an RINL antagonist has the potential to efficiently treat obesity. It is proposed for the first time that RINL is used as a new target in the preparation of a drug for treating obesity, which is of great significance for new drug screening, and also provides a new idea for the treatment of obesity.

The invention discloses an application of premna microphylla pectin in preparation of a product for preventing and improving diet-induced obesity. The premna pubescens pectin is prepared from premna pubescens leaves as a raw material through extraction, purification and other processes. According to the present invention, the research on the high fat diet induced obese mouse model finds that the body lipid metabolism is regulated by remodeling the intestinal flora structure, particularly reducing the ratio of the phylum firmicutes to the phylum bacteroides, and specifically enriching the beneficial flora such as Muribacaceae and the like by using the premna microphylla pectin; experimental results prove that the premna microphylla pectin can significantly inhibit pathological hypertrophy of adipocytes, reduce visceral fat accumulation, effectively control weight gain and improve dyslipidemia and liver fatty degeneration, and has good biological safety.

The invention relates to application of a fingered citron extract in preparation of a medicine for treating metabolic syndrome, and belongs to the technical field of biological medicines. According to the fingered citron extract disclosed by the invention, the diversity of flora can be improved by regulating intestinal flora, and the relative abundance of beneficial bacteria Akkermansia is specifically increased, so that the metabolic syndrome induced by high fat diet is relieved. An embodiment verifies that the scheme of the invention not only can significantly inhibit weight gain of obese mice induced by high fat diet, improve glucose metabolism disorder (including reduction of fasting blood-glucose and improvement of oral glucose tolerance), relieve liver fat accumulation and pathological damage, reduce visceral fat accumulation and improve adipocyte hypertrophy, but also can significantly inhibit the weight gain of the obese mice induced by high fat diet and improve the glucose metabolism disorder (including reduction of fasting blood-glucose and improvement of oral glucose tolerance). And obesity-related metabolic hormone disorder can be effectively reversed, for example, the serum insulin level is improved, and the leptin level is reduced.

The invention discloses a colorectal cancer postoperative risk assessment method, device and equipment and a storage medium, and relates to the technical field of colorectal cancer postoperative assessment, and the colorectal cancer postoperative risk assessment method comprises the following steps: based on a multi-head attention mechanism, segmenting a centrum horizontal CT image of a preoperative and postoperative third lumbar vertebra of a target object, and obtaining a centrum horizontal CT image of a second lumbar vertebra of the target object; obtaining a skeletal muscle area SMA, a visceral fat area VFA and a subcutaneous fat area SFA corresponding to preoperative and postoperative operations; respectively calculating a skeletal muscle index SMI and a visceral fat to subcutaneous fat ratio VSR according to SMA, VFA and SFA before and after the operation; according to the gender of the target object and the preoperative and postoperative SMI and VSR, judging whether the target object is sarcopenia and / or visceral fat obesity; and dividing risk levels according to preoperative and postoperative judgment results. Based on a multi-head attention mechanism, automatic accurate segmentation and risk assessment of the colorectal cancer postoperative body composition are realized, and the analysis efficiency and accuracy are remarkably improved.

The invention discloses a whole-body multi-end multi-frequency accurate visceral fat measuring method and device, and the method comprises the steps: configuring electrode pairs which comprise four groups of electrode pairs connected with four limbs and four groups of electrode pairs connected with the abdomen, and enabling sampling electrodes of the four groups of electrode pairs on the abdomen to be distributed at four points, the exciting electrodes of the four groups of electrode pairs on the abdomen are positioned outside the sampling electrodes; calculating the amount of non-visceral fat through the four groups of electrode pairs of the four limbs and the body weight; abdomen parameters are calculated through four groups of electrode pairs of the abdomen; and calculating the visceral fat mass according to the non-visceral fat mass and the abdominal parameters. According to the invention, the 16 electrodes are matched with the body weight sensor for measurement, and the non-visceral fat mass of the human body can be more accurately calculated through multi-dimensional and multi-frequency complex impedance measurement, so that the precision of visceral fat mass measurement is improved.

The present disclosure relates to treatment of Hypothalamic Obesity with Tesofensine alone or in combination with a beta-blocker. In particular the disclosure relates to treatments that lead to weight loss, loss of fat mass, in particular visceral fat, and to reduction of symptoms of pre-diabetes in patients suffering from Hypothalamic Obesity.

Provided is a novel preparation having an excellent lipolysis-promoting effect, an excellent visceral fat and body fat reducing effect, an excellent body weight reducing effect, and an excellent BMI improving effect. Another purpose of the present invention is to provide a novel preparation having an excellent insulin resistance improving effect, an excellent cholesterol value reducing effect, and the like. The present invention is an internal composition containing hirsutin B, which is used for at least one of lipolysis, fat burning, fat consumption assistance, BMI improvement, BMI reduction assistance, abdominal fat reduction, visceral fat reduction, body fat reduction, waist reduction, insulin resistance improvement, and LDL cholesterol value reduction. The internal composition of the present invention is preferably used for adults having a BMI of 23 kg / m < 2 > or more and less than 30 kg / m < 2 > and for adults having a visceral fat area of 100 cm < 2 > or more.

The invention relates to the field of environmental exposure omics and metabolic diseases, in particular to application of chlorpyrifos and paraquat in preparation of an abdominal obesity diagnosis product. The abdominal fat area, the A / S ratio, the liver fat content and other indexes measured through quantitative computed tomography (qCT) are combined, accurate recognition of abdominal obesity is achieved, the subjects with the normal body mass index (BMI) and visceral fat exceeding the standard can be effectively recognized, and the method has the advantages of being high in sensitivity, high in specificity and good in diagnosis foresight and has good application prospects. A new scheme is provided for early risk assessment and clinical screening of abdominal obesity, the significant correlation between the high exposure level of chlorpyrifos and paraquat and abdominal obesity supports the hypothesis that environmental endocrine disruptors promote obesity through metabolism interference, the urine concentration of chlorpyrifos and paraquat can be used as a novel biomarker, and the application prospect is broad. And a potential tool is provided for early screening of abdominal obesity.

A fat mass derivation device includes at least one processor, in which the processor derives a fat mass distribution of a subject from a first radiation image and a second radiation image acquired by imaging the subject with radiation having different energy distributions, and derives a visceral fat mass distribution of the subject based on a shape of the fat mass distribution in a cross section orthogonal to a body axis of the subject.

The invention belongs to the technical field of biological medicines, and discloses a novel application of an epimedium aqueous extract, icariin and icaritin in improvement of senescence-related fat accumulation and redistribution. The invention constructs a nematode-mouse dual verification model: firstly, in a caenorhabditis elegans model, it is found that the active ingredients can significantly reduce fat droplet accumulation and triglyceride level in senescence nematode bodies, and especially under the concentration of 50 [mu] M, icariin can reduce the triglyceride content of 15-day-old senescence nematode to 37.58% of a control group. Furthermore, a naturally aged mouse is evaluated by utilizing a high-resolution Micro-CT (VivaCT 80) living body imaging technology, and three-dimensional reconstruction and quantitative analysis prove that the medicine can remarkably reduce the volume of visceral fat in the abdomen of the aged mouse, effectively improve the ratio of visceral fat to subcutaneous fat (VAT / SAT ratio) and reverse central obesity caused by aging. The raw materials are from natural plants, have no obvious toxic or side effect after long-term administration, can accurately improve fat space distribution of aging organisms, and have significant clinical application value.

The present application belongs to the technical field of artificial intelligence medical treatment, and provides a visceral fat prediction method and system based on language model enhancement and a medium, comprising: acquiring baseline physiological data and a diet plan; generating semantic vectors for features through a pre-trained language model, and fusing the semantic vectors with numerical data to generate semantic enhancement features; predicting a first prediction result of visceral fat change through a first prediction model; acquiring early physiological response data in the middle of intervention; generating a second prediction result through a second prediction model in combination with the early response data; and generating personalized intervention suggestions based on comparison of the second prediction result with a preset threshold. The present application introduces biomedical semantics of features and constructs a two-stage dynamic prediction architecture, solves the problems of low prediction accuracy and inability to utilize feature biomedical semantics, significantly improves prediction accuracy, and realizes closed-loop personalized intervention guidance.

Methods and compositions using Dichrostachys glomerata or Cissus quadrangularis separately to provide a variety of health benefits, including but not limited to, increasing or up-regulating GLP-1 levels and reducing or decreasing DPP-4 activity, visceral fat, food intake, blood lipids, total cholesterol and total glucose in a mammal. In one embodiment, a composition for increasing or up-regulating GLP-1 levels in a mammal is provided where the composition comprises an effective amount of Cissus quadrangularis provided as an oral dosage unit in the form of a pill, capsule, liquid, lozenge or tablet.

The self-adaptive waistline measurement and visceral fat early warning waistband comprises a waistband body and a tightening measurement assembly, one end of the waistband body is wound in the tightening measurement assembly, and automatic tightening and retraction are achieved through a waistband winding assembly; the tightening measurement assembly is in signal connection with an electrode patch assembly, and the electrode patch assembly comprises a pair of excitation electrode patches, a pair of detection electrode patches and a patch pressure sensor used for monitoring contact pressure; a storage battery and a control main board are further arranged in the tightening measuring assembly shell. According to the device, the consistent tightening degree of the waistband during measurement is ensured through the patch pressure sensor, and the stretching length of the waistband is accurately measured through the angle sensor integrated on the clamping roller to obtain waistline data; a bioelectrical impedance measurement module in the control main board obtains human body impedance information through an electrode patch, an early warning and analysis module fuses waistline and impedance data, the visceral fat area is estimated through a built-in model, and risk early warning and personalized nutrition intervention suggestions are generated.

1. Name of the designed product: Body composition analysis instrument (BFA-9087). 2. Use of the designed product: used for analyzing the indicators of human body composition, evaluating health conditions, such as visceral fat, basal metabolism, body age, body water, muscle rate, skeletal muscle rate, etc. 3. Design points of the designed product: in shape. 4. Pictures or photos that best show the design points: perspective view.

Methods and compositions using Dichrostachys glomerata or Cissus quadrangularis separately to provide a variety of health benefits, including but not limited to, increase GLP-1 levels and reduce or decrease visceral fat, food intake, blood lipids, total cholesterol and total glucose in a mammal. In one embodiment, a composition for reducing visceral fat in a mammal is provided where the composition comprises an effective amount of Dichrostachys glomerata provided as an oral dosage unit in the form of a pill, capsule, liquid, lozenge or tablet.

Methods and compositions using Dichrostachys glomerata or Cissus quadrangularis separately to provide a variety of health benefits, including but not limited to, increase GLP-1 levels and reduce or decrease visceral fat, food intake, blood lipids, total cholesterol and total glucose in a mammal. In one embodiment, a composition for reducing fasting blood glucose in a mammal is provided where the composition comprises an effective amount of Cissus quadrangularis provided as an oral dosage unit in the form of a pill, capsule, liquid, lozenge or tablet.

The invention relates to the field of microorganisms, and discloses a lactobacillus paracasei (Lactobacillus paracasei) and an application of the lactobacillus paracasei in prevention, alleviation or treatment of sarcopenia. The probiotics can promote muscle protein synthesis, inhibit protein degradation, improve mitochondrial functions and reduce visceral fat accumulation by regulating and controlling AKT / mTOR, NF-kB, FOXO3a and other signal channels, so that muscle mass decline, function decline and inflammatory state induced by sarcopenia are remarkably relieved. In addition, the lactobacillus paracasei improves metabolic health and inflammatory status by reducing the level of proinflammatory factors (such as TNF-alpha and IL-6) and up-regulating the expression of anti-inflammatory factors (such as IL-10). The traditional Chinese medicine composition is suitable for muscle loss caused by senile sarcopenia, obesity sarcopenia and heat limitation, has the advantages of clear mechanism, high safety, stable curative effect and the like, and provides a novel adjuvant therapy scheme for clinic.

Methods and compositions using Dichrostachys glomerata or Cissus quadrangularis separately to provide a variety of health benefits, including but not limited to, increasing or up-regulating GLP-1 levels and reducing or decreasing DPP-4 activity, visceral fat, food intake, blood lipids, total cholesterol and total glucose in a mammal. In one embodiment, a composition for increasing or up-regulating GLP-1 levels in a mammal is provided where the composition comprises an effective amount of Dichrostachys glomerata provided as an oral dosage unit in the form of a pill, capsule, liquid, lozenge or tablet.

Methods and compositions using Dichrostachys glomerata or Cissus quadrangularis separately to provide a variety of health benefits, including but not limited to, increase GLP-1 levels and reduce or decrease visceral fat, food intake, blood lipids, total cholesterol and total glucose in a mammal. In one embodiment, a composition for reducing food intake or appetite in a mammal is provided where the composition comprises an effective amount of Dichrostachys glomerata provided as an oral dosage unit in the form of a pill, capsule, liquid, lozenge or tablet.

Methods and compositions using Dichrostachys glomerata or Cissus quadrangularis separately to provide a variety of health benefits, including but not limited to, increase GLP-1 levels and reduce or decrease visceral fat, food intake, blood lipids, total cholesterol and total glucose in a mammal. In one embodiment, a composition for reducing food intake or appetite in a mammal is provided, where the composition comprises an effective amount of Cissus quadrangularis provided as an oral dosage unit in the form of a pill, capsule, liquid, lozenge or tablet.

A machine for therapeutic treatments related to visceral fat reduction in a patient, equipped with four channels, each connected to electrodes for applying electromagnetic currents to a specific area of ​​the patient. This is achieved through the management of specific software that delivers a power value to each channel asynchronously, allowing for simultaneous readjustment of the power value of each of the four channels, depending on at least the energy flux emitted by the active electrodes (6) of each channel and the energy flux received from each of the passive electrodes (7) of the corresponding channels. Figure for the abbreviation: Fig. 2

The invention discloses application of visceral fat-derived UCHL5 as a myocardial fibrosis biomarker and a drug target, and belongs to the technical field of cardiovascular disease detection, prevention and treatment. From the perspective of fat-cardiac axis, it is proved for the first time that deubiquitinating enzyme UCHL5 from visceral fat (VAT) and entering circulation is a key promoting factor of angiotensin II (Ang II) related myocardial fibrosis, and it is proved that UCHL5 can be used as a body fluid biomarker for monitoring myocardial fibrosis and also is an anti-fibrosis target with medicinal properties. On the basis, UCHL5 can be applied to diagnosis, prevention and treatment of myocardial fibrosis as a biomarker and a drug target of myocardial fibrosis.